Epidemiology of Gastroesophageal Reflux Disease

Gastroenterology Clinics of North America

Volumn 43, Issue 1, 2014, Pages 1-14

  Rubenstein, Joel H ^a,b   Chen, Joan W ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cost; Esophageal neoplasms; Esophageal strictures; Incidence; Prevalence; Risk factors

Indexed keywords

COST; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL STRICTURES; INCIDENCE; PREVALENCE; RISK FACTORS;

ADENOCARCINOMA; BARRETT ESOPHAGUS; COST OF ILLNESS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HEALTH CARE COSTS; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 84895073479     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2013.11.006     Document Type: Review

References (72)

1. Vakil N., van Zanten S.V., Kahrilas P., Global Consensus Group, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900-1920. [quiz: 43].
2. El-Serag H.B. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007, 5:17-26.
3. El-Serag H.B., Sweet S., Winchester C.C., et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2013, 10.1136/gutjnl-2012-304269.
4. Ness-Jensen E., Lindam A., Lagergren J., et al. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut 2012, 61:1390-1397.
5. El-Serag H.B., Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998, 43:327-333.
6. Guda N.M., Vakil N. Proton pump inhibitors and the time trends for esophageal dilation. Am J Gastroenterol 2004, 99:797-800.
7. El-Serag H.B. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol 2006, 101:1727-1733.
8. El-Serag H.B., Lau M. Temporal trends in new and recurrent oesophageal strictures in a Medicare population. Aliment Pharmacol Ther 2007, 25:1223-1229.
9. Rubenstein J.H., Taylor J.B. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010, 32:1222-1227.
10. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
11. Pohl H., Sirovich B., Welch H.G. Esophageal adenocarcinoma incidence: are we reaching the peak?. Cancer Epidemiol Biomarkers Prev 2010, 19:1468-1470.
12. Bollschweiler E., Wolfgarten E., Gutschow C., et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001, 92:549-555.
13. Edgren G., Adami H.O., Weiderpass Vainio E., et al. Aglobal assessment of the oesophageal adenocarcinoma epidemic. Gut 2013, 62(10):1406-1414.
14. Rubenstein J.H., Scheiman J.M., Sadeghi S., et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol 2011, 106:254-260.
15. Hur C., Miller M., Kong C.Y., et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013, 119:1149-1158.
16. van Soest E.M., Dieleman J.P., Siersema P.D., et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005, 54:1062-1066.
17. Corley D.A., Kubo A., Levin T.R., et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009, 58:182-188.
18. Zagari R.M., Fuccio L., Wallander M.A., et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008, 57:1354-1359.
19. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129:1825-1831.
20. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122:1500-1511.
21. Everhart J.E., Ruhl C.E. Burden of digestive diseases in the United States. Part I: overall and upper gastrointestinal diseases. Gastroenterology 2009, 136:376-386.
22. Peery A.F., Dellon E.S., Lund J., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143:1179-1187.e1-3.
23. Dellon E.S., Carroll C.F., Allen J.K., et al. Adecade of increased gastrointestinal endoscopy utilization and costs in the United States, 2000-2009. Digestive Diseases Week 2012, (abstract), ASGE 67.
24. Sonnenberg A., Amorosi S.L., Lacey M.J., et al. Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database. Gastrointest Endosc 2008, 67:489-496.
25. Shaheen N.J., Hansen R.A., Morgan D.R., et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006, 101:2128-2138.
26. Heidelbaugh J.J., Goldberg K.L., Inadomi J.M. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol 2009, 104(Suppl 2):S27-S32.
27. Heidelbaugh J.J., Goldberg K.L., Inadomi J.M. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010, 16:e228-e234.
28. Heidelbaugh J.J., Kim A.H., Chang R., et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012, 5:219-232.
29. Heidelbaugh J.J., Metz D.C., Yang Y.X. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?. Int J Clin Pract 2012, 66:582-591.
30. Pasina L., Nobili A., Tettamanti M., et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011, 22:205-210.
31. Gawron A.J., Rothe J., Fought A.J., et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol 2012, 10:620-625. [quiz: e57].
32. Francis D.O., Rymer J.A., Slaughter J.C., et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol 2013, 108:905-911.
33. Joish V.N., Donaldson G., Stockdale W., et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin 2005, 21:535-544.
34. Henke C.J., Levin T.R., Henning J.M., et al. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000, 95:788-792.
35. Wahlqvist P., Carlsson J., Stalhammar N.O., et al. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD): results from a cross-sectional study. Value Health 2002, 5:106-113.
36. Dean B.B., Crawley J.A., Schmitt C.M., et al. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003, 17:1309-1317.
37. Wahlqvist P., Reilly M.C., Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther 2006, 24:259-272.
38. Wahlqvist P., Karlsson M., Johnson D., et al. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther 2008, 27:960-970.
39. Li Y.M., Du J., Zhang H., et al. Epidemiological investigation in outpatients with symptomatic gastroesophageal reflux from the Department of Medicine in Zhejiang Province, east China. JGastroenterol Hepatol 2008, 23:283-289.
40. Wong B.C., Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol 2006, 4:398-407.
41. Yamagishi H., Koike T., Ohara S., et al. Prevalence of gastroesophageal reflux symptoms in a large unselected general population in Japan. World J Gastroenterol 2008, 14:1358-1364.
42. Locke G.R., Talley N.J., Fett S.L., et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
43. Nouraie M., Razjouyan H., Assady M., et al. Epidemiology of gastroesophageal reflux symptoms in Tehran, Iran: a population-based telephone survey. Arch Iran Med 2007, 10:289-294.
44. Nocon M., Labenz J., Willich S.N. Lifestyle factors and symptoms of gastro-oesophageal reflux: a population-based study. Aliment Pharmacol Ther 2006, 23:169-174.
45. Trivers K.F., Sabatino S.A., Stewart S.L., et al. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer 2008, 123:1422-1428.
46. Zheng Z., Nordenstedt H., Pedersen N.L., et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology 2007, 132:87-95.
47. Nilsson M., Johnsen R., Ye W., et al. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut 2004, 53:1730-1735.
48. Kaltenbach T., Crockett S., Gerson L.B. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006, 166:965-971.
49. Kahrilas P.J., Gupta R.R. Mechanisms of acid reflux associated with cigarette smoking. Gut 1990, 31:4-10.
50. El-Serag H.B., Satia J.A., Rabeneck L. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut 2005, 54:11-17.
51. Murphy D.W., Castell D.O. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol 1988, 83:633-636.
52. Collings K.L., Pierce Pratt F., Rodriguez-Stanley S., et al. Esophageal reflux in conditioned runners, cyclists, and weightlifters. Med Sci Sports Exerc 2003, 35:730-735.
53. Clark C.S., Kraus B.B., Sinclair J., et al. Gastroesophageal reflux induced by exercise in healthy volunteers. JAMA 1989, 261:3599-3601.
54. Rokkas T., Pistiolas D., Sechopoulos P., et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007, 5:1413-1417.
55. Schutze K., Hentschel E., Dragosics B., et al. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut 1995, 36:831-833.
56. Labenz J., Blum A.L., Bayerdorffer E., et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997, 112:1442-1447.
57. Pandolfino J.E., Howden C.W., Kahrilas P.J. H. pylori and GERD: is less more?. Am J Gastroenterol 2004, 99:1222-1225.
58. Yaghoobi M., Farrokhyar F., Yuan Y., et al. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis. Am J Gastroenterol 2010, 105:1007-1013.
59. Raghunath A., Hungin A.P., Wooff D., et al. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003, 326:737.
60. Naylor G.M., Gotoda T., Dixon M., et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006, 55:1545-1552.
61. el-Omar E., Penman I., Ardill J., et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995, 109:681-691.
62. Rubenstein J.H., Inadomi J.M., Scheiman J., et al. Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 2013, 10.1016/j.cgh.2013.08.029.
63. Ruigomez A., Wallander M.A., Johansson S., et al. Irritable bowel syndrome and gastroesophageal reflux disease in primary care: is there a link?. Dig Dis Sci 2009, 54:1079-1086.
64. Hungin A.P., Hill C., Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2009, 30:331-342.
65. Havemann B.D., Henderson C.A., El-Serag H.B. The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut 2007, 56:1654-1664.
66. Martinez C.H., Han M.K. Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes. Med Clin North Am 2012, 96:713-727.
67. Karkos P.D., Leong S.C., Benton J., et al. Reflux and sleeping disorders: a systematic review. JLaryngol Otol 2009, 123:372-374.
68. Chan W.W., Chiou E., Obstein K.L., et al. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med 2011, 171:620-629.
69. Schey R., Dickman R., Parthasarathy S., et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. Gastroenterology 2007, 133:1787-1795.
70. Fass R., Quan S.F., O'Connor G.T., et al. Predictors of heartburn during sleep in a large prospective cohort study. Chest 2005, 127:1658-1666.
71. Zhang J., Lam S.P., Li S.X., et al. The longitudinal course and impact of non-restorative sleep: a five-year community-based follow-up study. Sleep Med 2012, 13:570-576.
72. Matsuki N., Fujita T., Watanabe N., et al. Lifestyle factors associated with gastroesophageal reflux disease in the Japanese population. JGastroenterol 2013, 48:340-349.